SCHEMBL17845557

SCHEMBL17845557

Cc1nsc(-n2c(=O)n(C)c3cc(F)ccc32)n1

nearest known ligand 0.53

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PARG Q86W56 11/20 0.53
MAPK14 Q16539 3/20 0.35
MEN1 O00255 1/20 0.35
HCRTR1 O43613 1/20 0.35
KMT2A Q03164 1/20 0.35
TP53 P04637 1/20 0.34
PKM P14618 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
GSR P00390 1/20 0.34
KDM4E B2RXH2 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
HSD17B10 Q99714 1/20 0.34
ATM Q13315 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17845285 0.82 PARG (0.54) PARGMEN1KMT2ATP53KDM4E
SCHEMBL17845486 0.77 PARG (0.52) PARG
SCHEMBL17845645 0.75 PARG (0.47) PARGTP53ALDH1A1
SCHEMBL17845719 0.72 PARG (0.55) PARG
SCHEMBL31650745 0.71 SMN1; SMN2 (0.55) MAPK14TP53PKMSMN1; SMN2KDM4E
SCHEMBL13355033 0.71 SMN1; SMN2 (0.55) MAPK14TP53PKMSMN1; SMN2KDM4E
SCHEMBL17845419 0.70 PARG (0.53) PARGMAPK14MEN1HCRTR1KMT2A
SCHEMBL31121949 0.70 PARG (0.53) PARGMAPK14MEN1HCRTR1KMT2A
SCHEMBL17845463 0.70 PARG (1.00) PARG
SCHEMBL31122004 0.70 PARG (1.00) PARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250223266-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2025-07-10 US disclosed
US-12129236-B2 PARG inhibitory compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2024-10-29 US disclosed
CN-112979631-B PARG inhibiting compounds 癌症研究科技有限公司 2024-09-20 CN disclosed
US-20210380539-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-12-09 US disclosed
US-20210380539-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-12-09 US disclosed
EP-3907224-A1 PARG INHIBITORY COMPOUNDS Cancer Research Technology Limited (GB) 2021-11-10 EP disclosed
EP-3907224-A1 PARG INHIBITORY COMPOUNDS Cancer Research Technology Limited (GB) 2021-11-10 EP disclosed
EP-3233845-B1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECH LTD (GB) 2021-07-21 EP disclosed
EP-3233845-B1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECH LTD (GB) 2021-07-21 EP disclosed
CN-112979631-A PARG inhibiting compounds 癌症研究科技有限公司 2021-06-18 CN disclosed
US-10995073-B2 PARG inhibitory compounds CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2021-05-04 US disclosed
CN-107295799-B PARG inhibiting compounds 癌症研究科技有限公司 2021-03-16 CN disclosed
US-20200165208-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2020-05-28 US disclosed
US-20200165208-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2020-05-28 US disclosed
US-20180194738-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-07-12 US disclosed
US-20180194738-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-07-12 US disclosed
US-20180194738-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2018-07-12 US disclosed
EP-3233845-A1 PARG INHIBITORY COMPOUNDS Cancer Research Technology Limited (GB) 2017-10-25 EP disclosed
WO-2016097749-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-06-23 WO disclosed
WO-2016097749-A1 PARG INHIBITORY COMPOUNDS CANCER RESEARCH TECHNOLOGY LIMITED (GB) 2016-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210380539-A1 PARG INHIBITORY COMPOUNDS PARP11, PARG, PARP16 PARG 2/4885MAPK14 4026/4885MEN1 640/4885
US-20180194738-A1 PARG INHIBITORY COMPOUNDS PARG, PARP11, PARP16 PARG 1/4885MAPK14 4012/4885MEN1 763/4885
US-10995073-B2 PARG inhibitory compounds PARG, PARP11, PARP16 PARG 1/4885MAPK14 4012/4885MEN1 763/4885
US-12129236-B2 PARG inhibitory compounds PARP11, PARG, PARP16 PARG 2/4885MAPK14 4026/4885MEN1 640/4885
US-20200165208-A1 PARG INHIBITORY COMPOUNDS PARG, PARP11, PARP16 PARG 1/4885MAPK14 4012/4885MEN1 763/4885
US-20250223266-A1 PARG INHIBITORY COMPOUNDS PARG, PARP11, PARP16 PARG 1/4885MAPK14 4012/4885MEN1 763/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.